<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661141</url>
  </required_header>
  <id_info>
    <org_study_id>BP1-01-01</org_study_id>
    <nct_id>NCT00661141</nct_id>
  </id_info>
  <brief_title>Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism</brief_title>
  <official_title>A Phase IIa, Prospective, Randomized, Blinded, Intra-Subject Controlled, Single Dose, Dose Escalation Study of Antizol® for Mitigation of Acetaldehyde Related Toxicity in Human Subjects With Symptoms of Inborn Altered Ethanol Metabolism With Concomitant Ethanol Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Pharma USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate if fomepizole (4-methylpyrazole) can treat symptoms associated with
      alcohol intolerance due to aldehyde dehydrogenase 2 (ALDH2) deficiency, an inherited
      metabolic disorder. These symptoms include flushing, nausea, headache, shortness of breath
      and dizziness, resulting from exposure to acetaldehyde, the primary metabolite of ethanol.
      Long-term, serious health risks have been associated with repeated exposure to acetaldehyde,
      a carcinogen, among ALDH2-deficient individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 32 subjects will be enrolled in ascending dosing cohorts of 8 subjects each.
      Each subject will receive an oral dose of study drug (fomepizole or placebo) with concomitant
      ethanol with group assignment in a randomized 1:1:1:1 ratio (2 subjects each group) on Study
      Day 1. Each subject is their own intra-subject control with the alternative study drug
      (fomepizole or placebo) administered on the next day (Study Day 2). Four subjects in each
      cohort will receive study drug (fomepizole or placebo) administered 30 minutes prior to
      ethanol, 4 with study drug (fomepizole or placebo) administered 30 minutes after ethanol. The
      study will assess safety and tolerability of fomepizole and the PK/PD of 4-MP, ethanol and
      acetaldehyde in the subject population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation</measure>
    <time_frame>Study Day 0 through Study Visit Day 7</time_frame>
    <description>AEs were collected to evaluate the safety and tolerability of oral Antizol with concomitant ethanol administration in particitpants with symptoms of acetaldehyde toxicity associated with altered ethanol metabolism. AE: any untoward medical event that occurs following the first administration of study medication until the study participant's last study visit, whether or not the event is considered drug related. SAE: an event that meets any of the following criteria: results in death; is life threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of an exposed subject; is medically significant or an important medical event as assessed by investigator or sponsor; is, in the opinion of the investigator, an important medical event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of 4-MP: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: Dose-Normalized (DN) Cmax</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: Time to Cmax (Tmax)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: Area Under the Plasma Concentration-Time Curve (AUC), Calculated to the Last Measured Concentration (AUC[0-t])</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: DN AUC(0-t)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: AUC, From Time 0 Extrapolated to Infinite Time (AUC[0-∞])</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: DN AUC(0-∞)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: Percentage of AUC0-∞ Obtained by Extrapolation (AUC%Extrap)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: Half-Life (T1/2)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: Apparent Clearance (CL/F)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of 4-MP: Apparent Volume of Distribution During Terminal Phase (Vz/F)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: Cmax</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: DN Cmax</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: Tmax</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: AUC(0-t)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: DN AUC(0-t)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: AUC(0-∞)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: DN AUC(0-∞)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: AUC%Extrap</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: T1/2</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: CL/F</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Ethanol: Vz/F</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: Cmax</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: DN Cmax</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: Tmax</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: AUC(0-t)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: DN AUC(0-t)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: AUC(0-∞)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: DN AUC(0-∞)</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: AUC%Extrap</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Acetaldehyde: T1/2</measure>
    <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Aldehyde Dehydrogenase-2 (ALDH2) Deficiency</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Antizol 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Antizol 3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Antizol 5.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Antizol 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antizol</intervention_name>
    <arm_group_label>Cohort 1: Antizol 1.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 2: Antizol 3.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 3: Antizol 5.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 4: Antizol 1.0 mg/kg</arm_group_label>
    <other_name>fomepizole</other_name>
    <other_name>4-methylpyrazole</other_name>
    <other_name>4-MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1: Antizol 1.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 2: Antizol 3.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 3: Antizol 5.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 4: Antizol 1.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>oral dose of ethanol (0.5 g/kg)</description>
    <arm_group_label>Cohort 1: Antizol 1.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 2: Antizol 3.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 3: Antizol 5.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort 4: Antizol 1.0 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age 21 to 50 years

          -  Subject of Japanese descent

          -  History of flushing, with or without palpitations, or nausea (Alcohol Sensitivity
             Screening Test ≥ 3.1) following occasional or inadvertent ethanol consumption either
             currently or in the past

          -  Subjects must be healthy volunteers with no other clinically relevant abnormalities as
             determined by medical history, blood chemistry, complete blood count (CBC),
             urinalysis,and 12-lead electrocardiogram (ECG)

          -  Positive skin ethanol patch test (100 μL of 70% ethanol on a lint pad applied to skin
             for 7 minutes results in an area of erythema)

          -  For Cohort 4, enrolled subjects were either homozygous or heterozygous for the ALDH2*2
             genotype as assessed by genotyping at Screening

        Exclusion Criteria:

          -  Vaccination within 2 weeks of Day 1

          -  Current respiratory disease or a past history of chronic respiratory disease, or
             current smoker within last six months

          -  Any one of the following Screening ECG findings:

               -  QTc (Bazett) interval duration greater than 450 msec (male) or 470 msec (female),
                  or

               -  QRS interval greater than 120 msec, or

               -  PR interval greater than 220 msec

          -  History or evidence of drug or alcohol abuse or regular consumption of more than 8
             units of alcohol daily (1 unit = 300 mL beer, 1 glass wine, 1 measure spirit) or those
             who may have difficulty abstaining from non study alcohol during the 36 hours prior to
             dose administration and until completion of blood sampling on Day 7

          -  Subjects who have donated blood totalling more than 550 mL within the 3 months prior
             to Day 1

          -  Use of any prescription medication other than oral contraceptives during the 14 days
             prior to Day 1, unless approved by both the Principal Investigator (PI) and the
             Sponsor

          -  Inability to abstain from smoking any tobacco product from within prior to 2 hours of
             blood sampling to after 2 hours of blood sampling during the study period.

          -  Use of any over-the-counter product, herbal product, diet aid, hormone supplement,
             etc., within 14 days prior to Day 1 unless approved by both the PI and the Sponsor

          -  Chronic use of pain medications

          -  Administration of an investigational agent within the last 30 days (or within a period
             of less than 5 times the agent's half-life, whichever is longer) prior to Day 1

          -  Major surgery within 60 days prior to Day 1, or any planned surgery or medical
             procedure during the study period (through Day 7)

          -  Positive alcohol breath-test or Positive drug screen (e.g., opiates, barbiturates,
             cannabinoids, benzodiazepines, cocaine, amphetamines) during screening or at Day 0
             Check-In

          -  Known hypersensitivity reaction to Antizol® or other pyrazoles, tomato juice

          -  Abnormal laboratory results, including:

               -  WBC ≤3.5 × 109/L or neutrophil count ≤2.0 × 10^9/L

               -  Hemoglobin &lt;12.0 or &gt;16.0 gm/dL

               -  Creatinine ≥2 mg/dL

               -  Total bilirubin ≥2 mg/dL

               -  Alanine aminotransferase and/or aspartate aminotransferase ≥2 times the upper
                  limit of normal

               -  PaO2 ≤95% on room air by pulse oximetry

               -  Urine dipstick positive for protein, blood, ketones, glucose or leukocyte
                  esterase

          -  Any other clinically significant abnormal result for hematology, clinical chemistry,
             or urinalysis at screening or check-In

          -  Positive serum pregnancy test for females of childbearing potential

          -  Subject and/or partner unable or unwilling to use an effective form of barrier
             contraceptives during the course of the study and for 7 days after study drug
             administration.

          -  Cancer (excluding adequately treated basal cell carcinoma) within the last 5 years

          -  Significant past medical history of hepatic, renal, cardiovascular (including family
             history of prolonged QT syndrome), pulmonary, gastrointestinal, hematological,
             locomotor, immunologic, ophthalmologic, metabolic endocrine or other diseases; or any
             condition that in the opinion of the Investigator would complicate or compromise the
             study, or the well-being of the subject

          -  Any other reason, which in the opinion of the Principal Investigator, would prevent
             the subject from completing or following the study schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Ruckle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Honolulu CRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Honolulu CRU</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Inoue K, Fukunaga M, Kiriyama T, Komura S. Accumulation of acetaldehyde in alcohol-sensitive Japanese: relation to ethanol and acetaldehyde oxidizing capacity. Alcohol Clin Exp Res. 1984 May-Jun;8(3):319-22.</citation>
    <PMID>6377951</PMID>
  </reference>
  <reference>
    <citation>Inoue K, Kera Y, Kiriyama T, Komura S. Suppression of acetaldehyde accumulation by 4-methylpyrazole in alcohol-hypersensitive Japanese. Jpn J Pharmacol. 1985 May;38(1):43-8.</citation>
    <PMID>4021229</PMID>
  </reference>
  <reference>
    <citation>Tardif R, Liu L, Raizenne M. Exhaled ethanol and acetaldehyde in human subjects exposed to low levels of ethanol. Inhal Toxicol. 2004 Apr;16(4):203-7.</citation>
    <PMID>15204767</PMID>
  </reference>
  <reference>
    <citation>Yokoyama T, Yokoyama A, Kato H, Tsujinaka T, Muto M, Omori T, Haneda T, Kumagai Y, Igaki H, Yokoyama M, Watanabe H, Yoshimizu H. Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1227-33.</citation>
    <PMID>14652286</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>May 22, 2013</results_first_submitted>
  <results_first_submitted_qc>August 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 15, 2017</results_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acetaldehyde</keyword>
  <keyword>ethanol</keyword>
  <keyword>ALDH2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Fomepizole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although originally planned to receive Antizol 7.0 mg/kg, participants in Cohort 4 were dosed with study drug (Antizol or placebo) at 1.0 mg/kg,the same level dosed for the Cohort 1 participants. As a result, Cohorts 1 and 4 were combined together in the data summary and statistical analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Antizol 1.0 mg/kg, Then Placebo</title>
          <description>Participants received Antizol 1.0 mg/kg then placebo treatment on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Antizol 1.0 mg/kg</title>
          <description>Participants received placebo treatment then Antizol 1.0 mg/kg on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="P3">
          <title>Antizol 3.0 mg/kg, Then Placebo</title>
          <description>Participants received Antizol 3.0 mg/kg then placebo treatment on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, Then Antizol 3.0 mg/kg</title>
          <description>Participants received placebo treatment then Antizol 3.0 mg/kg on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="P5">
          <title>Antizol 5.0 mg/kg, Then Placebo</title>
          <description>Participants received Antizol 5.0 mg/kg then placebo treatment on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Then Antizol 5.0 mg/kg</title>
          <description>Participants received placebo treatment then Antizol 5.0 mg/kg on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Administered 30 Minutes Prior to Ethanol</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Administered 30 Minutes After Ethanol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antizol 1.0 mg/kg and Placebo</title>
          <description>Participants received alternating study treatment (oral Antizol 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="B2">
          <title>Antizol 3.0 mg/kg and Placebo</title>
          <description>Participants receive alternating study treatment (oral Antizol 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="B3">
          <title>Antizol 5.0 mg/kg and Placebo</title>
          <description>Participants receive alternating study treatment (oral Antizol 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="28" upper_limit="50"/>
                    <measurement group_id="B2" value="29" lower_limit="22" upper_limit="44"/>
                    <measurement group_id="B3" value="34" lower_limit="23" upper_limit="43"/>
                    <measurement group_id="B4" value="34" lower_limit="22" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Not Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese Ancestry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Born in Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Born in Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation</title>
        <description>AEs were collected to evaluate the safety and tolerability of oral Antizol with concomitant ethanol administration in particitpants with symptoms of acetaldehyde toxicity associated with altered ethanol metabolism. AE: any untoward medical event that occurs following the first administration of study medication until the study participant’s last study visit, whether or not the event is considered drug related. SAE: an event that meets any of the following criteria: results in death; is life threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of an exposed subject; is medically significant or an important medical event as assessed by investigator or sponsor; is, in the opinion of the investigator, an important medical event.</description>
        <time_frame>Study Day 0 through Study Visit Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antizol 1.0 mg/kg</title>
            <description>Participants received alternating study treatment (oral Antizol 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
          </group>
          <group group_id="O2">
            <title>Antizol 3.0 mg/kg</title>
            <description>Participants received alternating study treatment (oral Antizol 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
          </group>
          <group group_id="O3">
            <title>Antizol 5.0 mg/kg</title>
            <description>Participants received alternating study treatment (oral Antizol 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
          </group>
          <group group_id="O4">
            <title>Pooled Placebo</title>
            <description>Participants received placebo on either Study Day 1 or Study Day 2, administered 30 minutes prior to, or after, ethanol.</description>
          </group>
          <group group_id="O5">
            <title>Overall</title>
            <description>Participants received alternating study treatment (oral Antizol 1.0, 3.0, or 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation</title>
          <description>AEs were collected to evaluate the safety and tolerability of oral Antizol with concomitant ethanol administration in particitpants with symptoms of acetaldehyde toxicity associated with altered ethanol metabolism. AE: any untoward medical event that occurs following the first administration of study medication until the study participant’s last study visit, whether or not the event is considered drug related. SAE: an event that meets any of the following criteria: results in death; is life threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of an exposed subject; is medically significant or an important medical event as assessed by investigator or sponsor; is, in the opinion of the investigator, an important medical event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-Threatening/Disabling AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly or Probably Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Study Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of 4-MP: Maximum Plasma Concentration (Cmax)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of 4-MP: Maximum Plasma Concentration (Cmax)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2386" spread="625"/>
                    <measurement group_id="O2" value="1358" spread="359"/>
                    <measurement group_id="O3" value="5605" spread="1183"/>
                    <measurement group_id="O4" value="4680" spread="645"/>
                    <measurement group_id="O5" value="8623" spread="2674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: Dose-Normalized (DN) Cmax</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: Dose-Normalized (DN) Cmax</title>
          <units>(ng/mL)/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="15.9"/>
                    <measurement group_id="O2" value="18.9" spread="4.65"/>
                    <measurement group_id="O3" value="27.6" spread="3.05"/>
                    <measurement group_id="O4" value="28.0" spread="4.26"/>
                    <measurement group_id="O5" value="30.2" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1.0 mg/kg Cohort, 3.0 mg/kg cohort, 5.0 mg/kg cohort</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8727</p_value>
            <p_value_desc>Overall p-value testing cohort difference from ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: Time to Cmax (Tmax)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: Time to Cmax (Tmax)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.333" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="1.53" upper_limit="4.43"/>
                    <measurement group_id="O3" value="0.667" lower_limit="0.333" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.48" lower_limit="0.500" upper_limit="2.50"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.333" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: Area Under the Plasma Concentration-Time Curve (AUC), Calculated to the Last Measured Concentration (AUC[0-t])</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: Area Under the Plasma Concentration-Time Curve (AUC), Calculated to the Last Measured Concentration (AUC[0-t])</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13804" spread="4492"/>
                    <measurement group_id="O2" value="7409" spread="1437"/>
                    <measurement group_id="O3" value="44942" spread="17784"/>
                    <measurement group_id="O4" value="34310" spread="14431"/>
                    <measurement group_id="O5" value="109298" spread="30635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: DN AUC(0-t)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: DN AUC(0-t)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>(ng*hr/mL)/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" spread="105"/>
                    <measurement group_id="O2" value="103" spread="16.6"/>
                    <measurement group_id="O3" value="231" spread="110"/>
                    <measurement group_id="O4" value="204" spread="83.1"/>
                    <measurement group_id="O5" value="378" spread="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1.0 mg/kg Cohort, 3.0 mg/kg cohort, 5.0 mg/kg cohort</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>Overall p-value testing cohort difference from ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.0 mg/kg Cohort, 3.0 mg/kg cohort</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.386</p_value>
            <p_value_desc>P-values for pairwise comparison between cohorts from ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1.0 mg/kg, 5.0 mg/kg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>P-values for pairwise comparison between cohorts from ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3.0 mg/kg, 5.0 mg/kg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0154</p_value>
            <p_value_desc>P-values for pairwise comparison between cohorts from ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: AUC, From Time 0 Extrapolated to Infinite Time (AUC[0-∞])</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: AUC, From Time 0 Extrapolated to Infinite Time (AUC[0-∞])</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11035">1 participant had an assessment</measurement>
                    <measurement group_id="O2" value="7627" spread="948"/>
                    <measurement group_id="O3" value="55452">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="57028">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="136871" spread="43703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: DN AUC(0-∞)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: DN AUC(0-∞)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>(ng*hr/mL)/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149">1 participant had an assessment</measurement>
                    <measurement group_id="O2" value="122" spread="9.15"/>
                    <measurement group_id="O3" value="317">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="334">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="460" spread="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: Percentage of AUC0–∞ Obtained by Extrapolation (AUC%Extrap)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: Percentage of AUC0–∞ Obtained by Extrapolation (AUC%Extrap)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8">1 participant had an assessment</measurement>
                    <measurement group_id="O2" value="13.0" spread="0.606"/>
                    <measurement group_id="O3" value="3.31">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="4.37">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="13.2" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: Half-Life (T1/2)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: Half-Life (T1/2)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72">1 participant had an assessment</measurement>
                    <measurement group_id="O2" value="3.11" spread="1.80"/>
                    <measurement group_id="O3" value="5.37">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="5.76">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="9.26" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: Apparent Clearance (CL/F)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: Apparent Clearance (CL/F)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.70">1 participant had an assessment</measurement>
                    <measurement group_id="O2" value="8.23" spread="0.618"/>
                    <measurement group_id="O3" value="3.15">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="2.99">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="2.35" spread="0.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of 4-MP: Apparent Volume of Distribution During Terminal Phase (Vz/F)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
        </group_list>
        <measure>
          <title>PK of 4-MP: Apparent Volume of Distribution During Terminal Phase (Vz/F)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3">1 participant had an assessment</measurement>
                    <measurement group_id="O2" value="24.7" spread="4.22"/>
                    <measurement group_id="O3" value="24.4">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="24.9">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="24.7" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: Cmax</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: Cmax</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="10.1"/>
                    <measurement group_id="O2" value="70.3" spread="4.99"/>
                    <measurement group_id="O3" value="80.5" spread="5.20"/>
                    <measurement group_id="O4" value="43.3" spread="9.54"/>
                    <measurement group_id="O5" value="74.9" spread="21.9"/>
                    <measurement group_id="O6" value="59.3" spread="15.4"/>
                    <measurement group_id="O7" value="55.1" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>115.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.45</ci_lower_limit>
            <ci_upper_limit>147.67</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>126.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.94</ci_lower_limit>
            <ci_upper_limit>155.87</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>137.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>115.66</ci_lower_limit>
            <ci_upper_limit>163.65</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>82.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.83</ci_lower_limit>
            <ci_upper_limit>108.07</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 participants in Cohort 3 had some residual 4-MP detected on Day 2 (Placebo treatment). As a result, the data for the participants on Day 2 were excluded from these statistical analyses, which could be compared with the analyses below where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>115.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.19</ci_lower_limit>
            <ci_upper_limit>145.67</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analyses for Cohort 3 where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>112.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.14</ci_lower_limit>
            <ci_upper_limit>131.98</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: DN Cmax</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: DN Cmax</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>(mg/dL)/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00195" spread="0.000448"/>
                    <measurement group_id="O2" value="0.00198" spread="0.000420"/>
                    <measurement group_id="O3" value="0.00243" spread="0.000453"/>
                    <measurement group_id="O4" value="0.00155" spread="0.000359"/>
                    <measurement group_id="O5" value="0.00261" spread="0.000871"/>
                    <measurement group_id="O6" value="0.00193" spread="0.000667"/>
                    <measurement group_id="O7" value="0.00175" spread="0.000543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: Tmax</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: Tmax</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.500" upper_limit="2.50"/>
                    <measurement group_id="O2" value="0.833" lower_limit="0.467" upper_limit="1.07"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                    <measurement group_id="O4" value="1.42" lower_limit="0.333" upper_limit="2.00"/>
                    <measurement group_id="O5" value="0.500" lower_limit="0.333" upper_limit="1.50"/>
                    <measurement group_id="O6" value="0.500" lower_limit="0.333" upper_limit="2.50"/>
                    <measurement group_id="O7" value="1.01" lower_limit="0.833" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: AUC(0-t)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: AUC(0-t)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>mg*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" spread="46.1"/>
                    <measurement group_id="O2" value="209" spread="24.2"/>
                    <measurement group_id="O3" value="205" spread="13.1"/>
                    <measurement group_id="O4" value="135" spread="44.0"/>
                    <measurement group_id="O5" value="231" spread="67.1"/>
                    <measurement group_id="O6" value="157" spread="53.2"/>
                    <measurement group_id="O7" value="152" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>139.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.18</ci_lower_limit>
            <ci_upper_limit>211.51</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>120.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>108.80</ci_lower_limit>
            <ci_upper_limit>134.03</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>143.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>107.72</ci_lower_limit>
            <ci_upper_limit>190.87</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>103.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.35</ci_lower_limit>
            <ci_upper_limit>126.10</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 participants in Cohort 3 had some residual 4-MP detected on Day 2 (Placebo treatment). As a result, the data for the participants on Day 2 were excluded from these statistical analyses, which could be compared with the analyses below where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>123.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>108.61</ci_lower_limit>
            <ci_upper_limit>139.67</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analyses for Cohort 3 where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>137.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>123.30</ci_lower_limit>
            <ci_upper_limit>152.59</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: DN AUC(0-t)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: DN AUC(0-t)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>(mg*hr/dL)/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00648" spread="0.00171"/>
                    <measurement group_id="O2" value="0.00585" spread="0.00115"/>
                    <measurement group_id="O3" value="0.00613" spread="0.000641"/>
                    <measurement group_id="O4" value="0.00483" spread="0.00155"/>
                    <measurement group_id="O5" value="0.00791" spread="0.00163"/>
                    <measurement group_id="O6" value="0.00508" spread="0.00194"/>
                    <measurement group_id="O7" value="0.00476" spread="0.00124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: AUC(0-∞)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: AUC(0-∞)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>mg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" spread="55.7"/>
                    <measurement group_id="O2" value="263" spread="27.2"/>
                    <measurement group_id="O3" value="237" spread="27.0"/>
                    <measurement group_id="O4" value="215" spread="27.9"/>
                    <measurement group_id="O5" value="271" spread="75.0"/>
                    <measurement group_id="O6" value="214" spread="47.4"/>
                    <measurement group_id="O7" value="198" spread="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>121.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>108.42</ci_lower_limit>
            <ci_upper_limit>136.84</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>123.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.55</ci_lower_limit>
            <ci_upper_limit>163.56</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>150.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.14</ci_lower_limit>
            <ci_upper_limit>242.63</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for Cohort 3 where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>122.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.45</ci_lower_limit>
            <ci_upper_limit>183.00</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: DN AUC(0-∞)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: DN AUC(0-∞)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>(mg*hr/dL)/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00760" spread="0.00199"/>
                    <measurement group_id="O2" value="0.00731" spread="0.000843"/>
                    <measurement group_id="O3" value="0.00705" spread="0.000437"/>
                    <measurement group_id="O4" value="0.00768" spread="0.000707"/>
                    <measurement group_id="O5" value="0.00917" spread="0.00166"/>
                    <measurement group_id="O6" value="0.00681" spread="0.00182"/>
                    <measurement group_id="O7" value="0.00617" spread="0.00120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: AUC%Extrap</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: AUC%Extrap</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="4.95"/>
                    <measurement group_id="O2" value="20.5" spread="6.90"/>
                    <measurement group_id="O3" value="13.2" spread="4.89"/>
                    <measurement group_id="O4" value="20.0" spread="4.68"/>
                    <measurement group_id="O5" value="12.1" spread="6.13"/>
                    <measurement group_id="O6" value="13.4" spread="5.62"/>
                    <measurement group_id="O7" value="13.9" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: T1/2</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: T1/2</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.391"/>
                    <measurement group_id="O2" value="1.95" spread="0.206"/>
                    <measurement group_id="O3" value="1.43" spread="0.219"/>
                    <measurement group_id="O4" value="1.78" spread="0.64"/>
                    <measurement group_id="O5" value="1.67" spread="0.608"/>
                    <measurement group_id="O6" value="1.45" spread="0.564"/>
                    <measurement group_id="O7" value="1.32" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: CL/F</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: CL/F</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>dL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" spread="36.8"/>
                    <measurement group_id="O2" value="138" spread="14.3"/>
                    <measurement group_id="O3" value="142" spread="8.81"/>
                    <measurement group_id="O4" value="131" spread="12.0"/>
                    <measurement group_id="O5" value="112" spread="19.6"/>
                    <measurement group_id="O6" value="159" spread="51.8"/>
                    <measurement group_id="O7" value="167" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Ethanol: Vz/F</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Ethanol: Vz/F</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure, received study assessments through Study Day 2, and who had available data.</population>
          <units>dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297" spread="82.8"/>
                    <measurement group_id="O2" value="387" spread="57.0"/>
                    <measurement group_id="O3" value="295" spread="55.4"/>
                    <measurement group_id="O4" value="330" spread="89.5"/>
                    <measurement group_id="O5" value="242" spread="79.1"/>
                    <measurement group_id="O6" value="287" spread="86.3"/>
                    <measurement group_id="O7" value="321" spread="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: Cmax</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: Cmax</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="34.4"/>
                    <measurement group_id="O2" value="37.6" spread="26.9"/>
                    <measurement group_id="O3" value="50.9" spread="52.8"/>
                    <measurement group_id="O4" value="55.9" spread="52.2"/>
                    <measurement group_id="O5" value="40.0" spread="16.6"/>
                    <measurement group_id="O6" value="60.3" spread="34.8"/>
                    <measurement group_id="O7" value="42.7" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>69.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.88</ci_lower_limit>
            <ci_upper_limit>97.78</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>124.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.77</ci_lower_limit>
            <ci_upper_limit>174.50</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>105.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.24</ci_lower_limit>
            <ci_upper_limit>124.27</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>88.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>56.66</ci_lower_limit>
            <ci_upper_limit>138.54</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 participants in Cohort 3 had some residual 4-MP detected on Day 2 (Placebo treatment). As a result, the data for the participants on Day 2 were excluded from these statistical analyses, which could be compared with the analyses below where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>70.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.16</ci_lower_limit>
            <ci_upper_limit>146.59</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analyses for Cohort 3 where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>86.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.78</ci_lower_limit>
            <ci_upper_limit>132.73</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: DN Cmax</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: DN Cmax</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>µM/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00181" spread="0.00101"/>
                    <measurement group_id="O2" value="0.00104" spread="0.000650"/>
                    <measurement group_id="O3" value="0.00157" spread="0.00167"/>
                    <measurement group_id="O4" value="0.00201" spread="0.00192"/>
                    <measurement group_id="O5" value="0.00138" spread="0.000542"/>
                    <measurement group_id="O6" value="0.00193" spread="0.00114"/>
                    <measurement group_id="O7" value="0.00141" spread="0.00112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: Tmax</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: Tmax</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.167" upper_limit="5.50"/>
                    <measurement group_id="O2" value="0.650" lower_limit="0.350" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.333" upper_limit="3.50"/>
                    <measurement group_id="O4" value="1.33" lower_limit="0.167" upper_limit="2.00"/>
                    <measurement group_id="O5" value="0.500" lower_limit="0.333" upper_limit="2.50"/>
                    <measurement group_id="O6" value="0.500" lower_limit="0.167" upper_limit="5.50"/>
                    <measurement group_id="O7" value="0.925" lower_limit="0.167" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: AUC(0-t)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: AUC(0-t)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>µM*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" spread="53.0"/>
                    <measurement group_id="O2" value="118" spread="56.4"/>
                    <measurement group_id="O3" value="155" spread="68.7"/>
                    <measurement group_id="O4" value="167" spread="84.4"/>
                    <measurement group_id="O5" value="128" spread="33.2"/>
                    <measurement group_id="O6" value="163" spread="61.3"/>
                    <measurement group_id="O7" value="139" spread="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>90.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.54</ci_lower_limit>
            <ci_upper_limit>117.00</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>112.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.72</ci_lower_limit>
            <ci_upper_limit>121.54</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>106.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.81</ci_lower_limit>
            <ci_upper_limit>116.24</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>104.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.50</ci_lower_limit>
            <ci_upper_limit>129.84</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 participants in Cohort 3 had some residual 4-MP detected on Day 2 (Placebo treatment). As a result, the data for the participants on Day 2 were excluded from these statistical analyses, which could be compared with the analyses below where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>100.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.86</ci_lower_limit>
            <ci_upper_limit>129.49</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analyses for Cohort 3 where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>94.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.70</ci_lower_limit>
            <ci_upper_limit>108.42</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: DN AUC(0-t)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: DN AUC(0-t)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>µM*hr/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00547" spread="0.00148"/>
                    <measurement group_id="O2" value="0.00329" spread="0.00144"/>
                    <measurement group_id="O3" value="0.00470" spread="0.00230"/>
                    <measurement group_id="O4" value="0.00597" spread="0.00293"/>
                    <measurement group_id="O5" value="0.00439" spread="0.00100"/>
                    <measurement group_id="O6" value="0.00521" spread="0.00204"/>
                    <measurement group_id="O7" value="0.00455" spread="0.00332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: AUC(0-∞)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: AUC(0-∞)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>µM*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" spread="64.4"/>
                    <measurement group_id="O2" value="154" spread="63.3"/>
                    <measurement group_id="O3" value="297">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="302">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="188" spread="28.1"/>
                    <measurement group_id="O6" value="205" spread="71.1"/>
                    <measurement group_id="O7" value="227" spread="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>94.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.01</ci_lower_limit>
            <ci_upper_limit>1113.63</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 participants in Cohort 3 had some residual 4-MP detected on Day 2 (Placebo treatment). As a result, the data for the participants on Day 2 were excluded from these statistical analyses, which could be compared with the analyses below where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>107.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.42</ci_lower_limit>
            <ci_upper_limit>131.10</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analyses for Cohort 3 where all available data were included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>ratio of parameter means</param_type>
            <param_value>97.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.84</ci_lower_limit>
            <ci_upper_limit>112.97</ci_upper_limit>
            <estimate_desc>Ratio of parameter means (Antizol/placebo, expressed as a percent), transformed back to the linear scale. 90% confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: DN AUC(0-∞)</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: DN AUC(0-∞)</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>µM*hr/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00682" spread="0.00203"/>
                    <measurement group_id="O2" value="0.00432" spread="0.00176"/>
                    <measurement group_id="O3" value="0.00929">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="0.0105">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="0.00626" spread="0.00110"/>
                    <measurement group_id="O6" value="0.00616" spread="0.00171"/>
                    <measurement group_id="O7" value="0.00752" spread="0.00360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: AUC%Extrap</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: AUC%Extrap</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="6.07"/>
                    <measurement group_id="O2" value="18.8" spread="8.11"/>
                    <measurement group_id="O3" value="13.1">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="9.78">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="24.7" spread="5.26"/>
                    <measurement group_id="O6" value="13.7" spread="5.29"/>
                    <measurement group_id="O7" value="14.5" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Acetaldehyde: T1/2</title>
        <time_frame>Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment</time_frame>
        <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.0 mg/kg Antizol Followed by Ethanol</title>
            <description>1.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O2">
            <title>Ethanol Followed by 1.0 mg/kg Antizol</title>
            <description>Ethanol followed by 1.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg/kg Antizol Followed by Ethanol</title>
            <description>3.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Ethanol Followed by 3.0 mg/kg Antizol</title>
            <description>Ethanol followed by 3.0 mg/kg Antizol 30 minutes later</description>
          </group>
          <group group_id="O5">
            <title>5.0 mg/kg Antizol Followed by Ethanol</title>
            <description>5.0 mg/kg Antizol followed by ethanol 30 minutes later</description>
          </group>
          <group group_id="O6">
            <title>Placebo Followed by Ethanol</title>
            <description>Placebo followed by ethanol 30 minutes later.</description>
          </group>
          <group group_id="O7">
            <title>Ethanol Followed by Placebo</title>
            <description>Ethanol followed by placebo 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Acetaldehyde: T1/2</title>
          <population>Modified Intent-to-Treat: participants who received any study medication or procedure and who received study assessments through Study Day 2.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="0.729"/>
                    <measurement group_id="O2" value="3.08" spread="0.640"/>
                    <measurement group_id="O3" value="2.48">1 participant had an assessment</measurement>
                    <measurement group_id="O4" value="1.72">1 participant had an assessment</measurement>
                    <measurement group_id="O5" value="3.45" spread="3.43"/>
                    <measurement group_id="O6" value="2.39" spread="0.521"/>
                    <measurement group_id="O7" value="2.09" spread="0.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from Check-In (Study Day 0) through Study Visit Day 7/Study End Visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Antizol 1.0 mg/kg</title>
          <description>Participants received alternating study treatment (oral Antizol 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="E2">
          <title>Antizol 3.0 mg/kg</title>
          <description>Participants received alternating study treatment (oral Antizol 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.</description>
        </group>
        <group group_id="E3">
          <title>Antizol 5.0 mg/kg</title>
          <description>Participants received alternating study treatment (oral Antizol 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
        </group>
        <group group_id="E4">
          <title>Pooled Placebo</title>
          <description>Participants received placebo on either Study Day 1 or Study Day 2), administered 30 minutes prior to ethanol.</description>
        </group>
        <group group_id="E5">
          <title>Overall</title>
          <description>Participants received alternating study treatment (oral Antizol 1.0, 3.0, or 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Respiratory rate increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood LDH increased</sub_title>
                <description>lactic acid dehydrogenase (LDH)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors’ Intellectual Property rights .</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beth Robinson, Executive Director</name_or_title>
      <organization>Horizon Pharma USA, Inc.</organization>
      <email>clinicaltrials@horizonpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

